CSIMarket Company Name, Ticker, Competitors, else..
 
Praxis Precision Medicines Inc   (NASDAQ: PRAX)
Other Ticker:  
 
 
Price: $36.0000 $0.00 0.000%
Day's High: $36.86 Week Perf: 0.28 %
Day's Low: $ 34.85 30 Day Perf: -5.73 %
Volume (M): 301 52 Wk High: $ 91.83
Volume (M$): $ 10,818 52 Wk Avg: $57.35
Open: $35.36 52 Wk Low: $26.70



 Market Capitalization (Millions $) 645
 Shares Outstanding (Millions) 18
 Employees 82
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -183
 Cash Flow (TTM) (Millions $) 134
 Capital Exp. (TTM) (Millions $) 0

Praxis Precision Medicines Inc
Praxis Precision Medicines Inc is a biopharmaceutical company focused on discovering and developing targeted therapies for patients suffering from central nervous system disorders. The company leverages its expertise in neuroscience and genetic research to identify novel drug targets and develop precision medicines that address the underlying causes of these disorders. Praxis aims to provide patients with personalized treatments that can improve their quality of life.


   Company Address: 99 High Street Boston 2110 MA
   Company Phone Number: 300-8460   Stock Exchange / Ticker: NASDAQ PRAX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD        1.87% 
ALKS        3% 
BMRN        3% 
IONS        3% 
PTCT        3.25% 
SRPT        9.75% 
• View Complete Report
   



Shares

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published Thu, Apr 3 2025 8:00 PM UTC

Praxis Precision Medicines: Strategic Stock Award to Enhance Team Capabilities Amid Promising Epilepsy BreakthroughsIn a recent development poised to influence both its human resources and financial narratives, Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a frontrunner in the biopharmaceutical field, has initiated significant stock-based incentives to bolster its talent...
Clinical Study

Transforming Epilepsy Treatment Praxis Precision Medicines Promising Breakthrough and Financial Journey

Published Tue, Sep 3 2024 11:30 AM UTC

In a significant stride towards innovative epilepsy management, Praxis Precision Medicines has unveiled promising topline results from its EMBOLD study, showcasing the disease-modifying potential of relutrigine for patients diagnosed with SCN2A and 8A developmental epilepsies. The study reported an impressive placebo-adjusted monthly motor seizure reduction of 46% during its...
Shares

Praxis Precision Medicines Grants Stock Options and Restricted Stock Units to New Employee in Line with Nasdaq Listing Rule 5635(c)(4)

Published Tue, Jun 4 2024 9:00 PM UTC

Praxis Precision Medicines Grants Stock Options and Restricted Stock Units to New Employee
BOSTON, June 4, 2024 - Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a pioneering clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, has announced the gran...
Praxis Precision Medicines Inc

Praxis Precision Medicines Inc Reports Sharp Decline in Top-line Revenue for Q1 2024

Praxis Precision Medicines Inc recently reported disappointing financial results for the first quarter of 2024, with a significant decrease in revenue and an increase in net deficit compared to the same period last year. The company's revenue dropped by -36.896% to $0.43 million, and the shortfall per share improved to $-2.84 from $-10.65 in the previous year. However, the deficit per share increased compared to the preceding reporting period, rising from $-1.78.
Despite these challenges, Praxis Precision Medicines Inc is looking towards the future with plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and the first half of 2025. This highlights the company's commitment to advancing research and innovation in the field of central nervous system disorders.
Shares

Praxis Precision Medicines Announces Inducement Grants and Pricing of Public Offering

Published Fri, May 3 2024 8:45 PM UTC



Praxis Precision Medicines, a clinical-stage biopharmaceutical company specializing in the development of therapies for central nervous system disorders, has made significant announcements regarding inducement grants and a public offering. The company aims to leverage its genetic insights to address the imbalances in neuronal excitation and inhibition. With a focus...






Praxis Precision Medicines Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com